Brain Tumor, Kidney Tumor, Neuroblastoma, Sarcoma
Conditions
Brief summary
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
Interventions
PROCEDURESkin biopsy
Skin biopsy
PROCEDUREFresh tumor sample
Fresh tumor sample
BIOLOGICALBlood sample
Blood sample in heparin tubes (highly recommended), to be collected before starting treatment or as soon as hematological recovery has been reached
PROCEDUREHealthy tissue from the tumor
Healthy tissue from the tumor site whenever possible
PROCEDURESpinal cerebrospinal fluid (SCF)
Spinal cerebrospinal fluid (SCF) whenever possible
Sponsors
Gustave Roussy, Cancer Campus, Grand Paris
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 25 Years
Healthy volunteers
No
Inclusion criteria
* Age at diagnosis ≤ 25 years except for patients with malignant gliomas and renal tumors for whom no upper age limit is applied * Medical suspicion or diagnosis of one of the following diseases, regardless of stage: * Brain tumors * Renal tumors * Neuroblastoma * Sarcomas * Adult patient or parents or guardians should understand, sign and date the appropriate written informed consent from prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol. * Affiliated to a social security system or beneficiary of the same.
Exclusion criteria
* Any histology not mentioned in the inclusion criteria * Adult patient or parents/guardians incapable/incapable of giving its/their consent * Patients deprived of their liberty by a judicial or administrative decision
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of viable and exploitable immune organoids with engrafted tumor cells | until 5 years after enrolment |
Countries
France
Contacts
CONTACTClaudia PASQUALINI, MD
CONTACTJérémy MIONE, MS
Outcome results
None listed